At the archive date, THERMO FISHER SCIENTIFIC INC. was expected to release its Q3 2026 10-Q filing on October 20, 2026, before market open. Last quarter: Thermo Fisher Scientific reported strong Q2 FY2026 financial results, with revenue increasing 10.5% YoY to $11.99B and diluted EPS rising 9.3% YoY to $4.68, driven by robust pharma and biotech market demand and strategic M&A integration.
EPS Estimate
$6.47
Revenue Estimate
$12.06B
Analyst consensus captured from Finnhub and Financial Modeling Prep. This archived preview is no longer updated with later results; see the TMO page for retained reports.
Drawn from management commentary in the Q2 2026 10-Q:
Q2 FY2026 consolidated revenue reached $11.99B, up 10.5% YoY (5% organic growth, 5% acquisition impact, 1% FX). Growth was led by the Laboratory Products and Biopharma Services segment ($6.69B, up 12% YoY) and the Life Sciences Solutions segment ($2.82B, up 13% YoY), driven by strengthening customer demand in pharma and biotech markets.
GAAP operating income increased 13.8% YoY to $2.09B, with GAAP operating margin expanding 50 bps YoY to 17.40%. Non-GAAP Adjusted Operating Margin reached 22.8% (up 90 bps YoY), primarily driven by Practical Process Improvement (PPI) system productivity gains, partially offset by unfavorable business mix.
On March 24, 2026, Thermo Fisher completed the acquisition of Clario Holdings, Inc. within the Laboratory Products and Biopharma Services segment, adding $441M in reported revenue for the clinical research business in Q2 FY2026. This complements the September 2025 acquisition of the filtration and separation business from Solventum Corporation.
Revenue
$11.99B
+10.49% YoY
EPS (Diluted)
$4.68
+9.35% YoY
Operating Income
$2.09B
+13.79% YoY
Add TMO to your watchlist to keep its archived reports easy to find. New filing alerts are no longer sent.